Webinar Overview
Biomarkers are a significant driver of success in clinical development, but when should you start investigating biomarkers in the drug development process? Should you start as early as target discovery to fully benefit from candidate biomarkers already in lead selection, and run the risk of spending resources before an asset is confirmed? And how can biomarkers be truly translatable, from in vitro to in vivo to clinical application?
In this webinar, we will discuss potential synergies between biomarker and drug discovery activities, from target discovery through safety studies. We will explore strategies to deploy early biomarker candidates in lead selection and preclinical pharmacology for early de-risking of drug development programs and setting up for success in clinical development. We will also review the critical scientific questions that drive biomarker strategy and inform on the optimal approach of biomarker discovery.
Register today to learn more about different biomarker discovery approaches in the various stages of drug discovery and development.
This webinar will show you:
- How biomarkers drive the probability of success in clinical development
- How to integrate biomarker discovery into the drug discovery process
- How biomarkers can impact translational success from in vitro to in vivo to clinical application
- How neurofilament light is fulfilling a variety of biomarker purposes in different stages of drug development
Webinar Presenters
Stefan Kostense
Director Biology
Charles River
Philip Mitchell
Science Director
Charles River